Терапия №8 / 2026
Azithromycin in asthma: Anti-inflammatory and immunomodulatory mechanisms and therapeutic potential
North Ossetian State Medical Academy, Vladikavkaz, Russian Federation
Introduction
Asthma is a chronic respiratory disease characterized by chronic inflammation of the respiratory tract, such symptoms as shortness of breath, wheeze, chest tightness and/or cough, and variable expiratory airflow limitations. The main goal of modern asthma therapy is to achieve and maintain control over asthma symptoms over the long term and to minimize the risks of future asthma exacerbations, fixed airway obstruction, and undesirable side effects from the therapy being administered. Inhaled corticosteroids (ICS) alone or in combination with long-acting β2-agonists (LABA) and leukotriene receptor antagonists form the basis of asthma pharmacotherapy [1, 2]. In most patients, this treatment makes it possible to achieve asthma control, but about 3–10% of patients fail to have the desired results. Patients with severe asthma experience frequent and severe exacerbations despite good adherence to maintenance treatment and often require additional therapies to achieve disease control. Azithromycin (AZM) is recommended to enhance therapy for uncontrolled asthma in patients with persistent symptoms or exacerbations despite correct inhaler technique and good adherence on Step 4 treatment [1, 2]. There is data confirming that AZM add-on treatment of poorly controlled asthma due to its anti-inflammatory properties reduces the number of exacerbations and the need for systemic corticosteroids in patients with severe asthma, however, the benefits and risks of using AZM for the management of asthma remain not fully understood [3–5].
AZITHROMYCIN PHARMACOLOGY
Structure
The basic of structure of macrolides is a macrocyclic lactone ring containing a different number of carbon atoms. Depending on the number of carbon atoms in the ring, macrolides are divided into 14-, 15- or 16-membered polyhydroxylactones [6, 7].
AZM is a 15‑membered macrolide (azalide) produced by replacing carbonyl(9a) in the aglycone ring with methyl nitrogen. Its chemical formula is C38H72N2O12 (9-deoxo-9a-methyl-9a-aza-9a-homo erythromycin A) (Fig. 1).
Mechanism of action and pharmacological effects
Like other representatives of the macrolide class AZM inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S ribosomal subunit, which is located directly next to the peptidyltransferase center and serves as a tunnel for the exit of the synthesized peptide chain. It blocks the tunnel’s lumen and prevents the elongated polypeptide chain from passing through it, exerting a bacteriostatic or bactericidal effect – this depends on dosage regimen and/or microorganism. The spectrum of antimicrobial activity of AZM includes S. pyogenes, S. pneumoniae, S. aureus (with the exception of methicillin‑resistant strains), B. pertussis, M. catarrhalis, H. pylori, L. pneumophila, Mycoplasma spp., Chlamydia spp., U. urealyticum, L. monocytogenes. Furthermore, AZM is characterized by non‑antibacterial activity, which includes immunomodulatory and anti‑inflammatory effects (Fig. 2) [6, 7].
Pharmacokinetics
The pharmacokinetic properties of AZM differ from those of other macrolide antibiotics. All macrolides are tissue‑active antibiotics; their concentrations in blood serum are significantly lower than in tissues, and azithromycin has the lowest serum concentrations among all drugs in this group. It is rapidly accumulated by cells and tissues, particularly by blood leukocytes, and is slowly released from these sites with plasma half-life 35–55 h [7].
IMMUNOMODULATORY AND ANTI‑INFLAMMATORY ACTIVITY OF AZITHROMYCIN
For the first time, the anti‑inflammatory and immunomodulatory properties of macrolides were described in 1987, when the unexpected effect of erythromycin (ERY) was reported in patient with diffuse panbronchiolitis, induced by gram‑negative cocci. As we know, these bacteria are in most cases resistant to ERY, so its effectiveness was considered due to anti‑inflammatory action [8]. The inclusion of ERY in clinical practice as a standard therapy for diffuse panbronchiolitis has led to an increase in 10‑year survival rate from 10–20% to 90% [9, 10]. The further results of subsequent experimental and clinical studies have shown that 14- and 15-membered macrolides are characterized by anti-inflammatory and immunomodulatory effects, which manifest when small doses of the antibiotic are used over a long period of time (at least 3 months) [11–13].
The immunomodulatory effects of macrolides are based on suppression of neutrophilic inflammation. Reduction in the number of neutrophils and inhibition of their function lead to a decrease in concentration of neutrophil elastase and interleukin 8 (IL‑8), which causes the migration of neutrophils and basophils to the site of inflammation and their degranulation, the release of superoxide radicals, and the stimulation of angiogenesis [14].
AZM has immunomodulatory and anti‑inflammatory activity and is one of the most studied macrolides in terms of these properties.
The effect of...











